If you have been reading about circadian rhythm and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-04-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine in major jurisdictions | Sold as a research chemical; legal status varies |
| Anti-doping status | Prohibited by the World Anti-Doping Agency | Listed under non-approved substances or related category |
| Typical analytical method | LC-MS/MS | Used for detection and confirmation in biological samples |
| Storage temperature | −20 °C or lower for solid | Desiccated and protected from light |
| Common solution solvents | DMSO; ethanol | Aqueous solubility is limited |
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
FGFR1 oncogene partner 2 (FGFR1OP2) is a protein that in humans is encoded by the gene FGFR1OP2. It was identified in a study on myeloproliferative syndrome (EMS). The study aimed to identify the partner genes to the fibroblast growth factor receptor 1 (FGFR1) involved in the syndrome. Using the 5'-RACE PCR technique, FGFR1OP2 was identified as a novel gene with no known function.
== Chemistry == KNX-100 is a synthetic small molecule and peptide fragment of the oxytocin system. Its chemical structure has been disclosed by its developers in a patent. The chemical synthesis of KNX-100 has been described. The small-molecule oxytocin receptor agonists LIT-001 and LIT-002 are derivatives of KNX-100. The more-compact small-molecule oxytocin receptor agonists WJ0679 and CA7 are also analogues of KNX-100.
=== Climate change === Bhutto Zardari has proposed a plan to "completely restructure Pakistan's economic development model, putting the threat of climate change front and centre." His party's election manifesto aims to ensure that funds exceeding $10 billion are directed to fighting climate change, in the wake of the 2022 Pakistan floods that displaced more than 7 million people.
Sources: en.wikipedia.org
== Synthetic blood plasma == Simulated body fluid (SBF) is a solution having a similar ion concentration to that of human blood plasma. SBF is normally used for the surface modification of metallic implants, and more recently in gene delivery application.
== Epidemiology == Weissenbacher-Zweymüller syndrome affects males and females in the same numbers. About 30 cases have been reported in medical literature. The disorder can be underdiagnosed causing no true frequency in the population.
==== Black People's Convention ==== In August 1971, Biko attended a conference on "The Development of the African Community" in Edendale. There, a resolution was presented calling for the formation of the Black People's Convention (BPC), a vehicle for the promotion of Black Consciousness among the wider population. Biko voted in favour of the group's creation but expressed reservations about the lack of consultation with South Africa's Coloureds or Indians. A. Mayatula became the BPC's first president; Biko did not stand for any leadership positions. The group was formally launched in July 1972 in Pietermaritzburg. By 1973, it had 41 branches and 4000 members, sharing much of its membership with SASO.
Sources: en.wikipedia.org
=== Biochemistry === In proteomics, MALDI is used for the rapid identification of proteins isolated by using gel electrophoresis: SDS-PAGE, size exclusion chromatography, affinity chromatography, strong/weak ion exchange, isotope coded protein labeling (ICPL), and two-dimensional gel electrophoresis. Peptide mass fingerprinting is the most popular analytical application of MALDI-TOF mass spectrometers. MALDI TOF/TOF mass spectrometers are used to reveal amino acid sequence of peptides using post-source decay or high energy collision-induced dissociation (further use see mass spectrometry). MALDI-TOF have been used to characterise post-translational modifications. For example, it has been widely applied to study protein methylation and demethylation. However, care must be taken when studying post-translational modifications by MALDI-TOF. For example, it has been reported that loss of sialic acid has been identified in papers when dihydroxybenzoic acid (DHB) has been used as a matrix for MALDI MS analysis of glycosylated peptides. Using sinapinic acid, 4-HCCA and DHB as matrices, S. Martin studied loss of sialic acid in glycosylated peptides by metastable decay in MALDI/TOF in linear mode and reflector mode. A group at Shimadzu Corporation derivatized the sialic acid by an amidation reaction as a way to improve detection sensitivity and also demonstrated that ionic liquid matrix reduces a loss of sialic acid during MALDI/TOF MS analysis of sialylated oligosaccharides.
During the 2025 legislative session, Moore introduced the Excellence in Maryland Public Schools Act, which proposed temporary pauses on plans under the Blueprint to gradually give teachers more "collaborative time" to work on professional development and planning outside of the classroom, reduce funding for programs to support students learning English, and freeze funding for community schools for two years. These proposed changes would cut nearly one-fifth of new funding provided under the Blueprint reforms and have the most impact on students living in poverty and immigrant students. Moore's proposed Blueprint reforms were largely rejected by lawmakers, who amended Moore's bill to reinstate funding for community schools and students learning English, but implemented a three-year delay on collaborative time implementation plans. Moore signed the Excellence in Maryland Public Schools Act into law in May 2025.
==== UPMC Salvator Mundi ==== UPMC Salvator Mundi International Hospital 75-bed private hospital in Rome, Italy, that is jointly owned by UPMC and Rome International Hospital Management Srl. UPMC owns a 50% stake in the hospital and leads its medical operations including having responsibility for selecting its medical director and chief operating officer.
Sources: en.wikipedia.org
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.
Laboratories typically use LC-MS/MS to detect SR9009 and related compounds in urine or blood. The method is sensitive but depends on sample collection timing. Confirmatory analysis follows quality-control procedures.
Solid material is generally kept cold, dry, and protected from light. Solutions are often stored in sealed containers at low temperature. Stability beyond recommended periods is not well documented.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.